As GW842166x was found to be safe and well-tolerated with no serious adverse effects in clinical trials [27], our study raises the exciting possibility that GW842166x or other CB2 agonists may be utilized as a neuroprotective treatment during the early phase of PD to slow disease progression. Here, CNR2 is linked to Parkinson disease.